

JBF(CMD) 1050



19

PLEASE STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

New U.S. Patent Application for: **APOPTOSIS INDUCER AND METHOD OF SCREENING FOR A SUBSTANCE INHIBITING ACYLATED HOMOSERINE LACTONE**

Inventors: 1) Nobuhiko NOMURA and 2) Hitoshi MIYAZAKI

MAIL STOP PATENT APPLICATION

1. Check for \$770.00
2. Transmittal Letter
3. Spec. 42 pgs. 3 indep. clms. and 11 clms. total
4. Drawings - 19 sheets of drawings containing 19 figures (Figure 14 is color photo)
5. Preliminary Amendment
6. Petition To Accept Color Photographs (Three sets of Figure 14, color photo)
7. Certified copies of Japanese Patent Application Nos. 2003-021047, filed January 29, 2003, and 2003-021053, filed on January 29, 2003

Dated: **January 28, 2004**
Docket No.: **04853.0111**
CUSTOMER NUMBER: 22,852
JBF/FPD/sci - Mail Drop 360



(Due Date: **January 29, 2004**)

OK 70
1/29/04
[Signature]

[Signature]

Commissioner for Patents

January 28, 2004

Page 2

**FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER^{LLP}**

6. The filing fee is calculated as follows:

| | | | | | | |
|--|------------------|---|-------|--------------|--------|-------------|
| Basic Application Filing Fee | | | | | \$770 | \$ \$770.00 |
| | Number of Claims | | Basic | Extra Claims | | |
| Total Claims | 11 | - | 20 | 0 | x \$18 | |
| Independent Claims | 3 | - | 3 | 0 | x \$86 | |
| <input type="checkbox"/> Presentation of Multiple Dep. Claim | | | | | +\$290 | |
| Subtotal | | | | | | \$ 770.00 |
| Reduction by 1/2 if small entity | | | | | | - |
| TOTAL APPLICATION FILING FEE | | | | | | \$ 770.00 |

7. A check for \$770.00 is enclosed for filing fee.

This application is being filed under the provisions of 37 C.F.R. § 1.53(f). Applicants await notification from the Patent and Trademark Office of the time set for filing the Declaration.

Applicants claim the right to priority based on Japanese Patent Application Nos. 2003-021047, filed on January 29, 2003, and 2003-021053, filed on January 29, 2003, respectively.

Please address all correspondence with respect to this application to:

**Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
1300 I Street, N.W.
Washington, D.C. 20005-3315**

Please accord this application an application number and filing date.



FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

Attachment 1

1300 I Street, NW ■ Washington, DC 20005-3315 ■ 202.408.4000 ■ Fax 202.408.4400
www.finnegan.com

ERNEST E. CHAPMAN
202.408.4096



January 28, 2004

ATTORNEY DOCKET NO. 04853.0111
CUSTOMER NO. 22,852

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

New U.S. Patent Application

Title: **APOPTOSIS INDUCER AND METHOD OF SCREENING FOR A
SUBSTANCE INHIBITING ACYLATED HOMOSERINE LACTONE**

Inventors and Addresses:

- 1) **Nobuhiko NOMURA**
Tsukuba-shi, Japan
- 2) **Hitoshi MIYAZAKI**
Tsukuba-shi, Japan

Sir:

We enclose the following papers for filing in the United States Patent and Trademark Office in connection with the above patent application.

1. Application - 42 pages, including 3 independent claims and 11 claims total.
2. Drawings - 19 sheets of drawings containing 19 figures (Figure 14 is color photo).
3. Preliminary Amendment.
4. Petition To Accept Color Photographs (Three sets of Figure 14, color photo).
5. Certified copies of Japanese Patent Application Nos. 2003-021047, filed on January 29, 2003, and 2003-021053, filed on January 29, 2003, respectively.

b) an animal cell, and


c) a means for measuring Akt activity.

9. (Withdrawn) A substance inhibiting acylated homoserine lactone, which is identified by the screening method of claim 5.

10. (Withdrawn) An acylated homoserine lactone inhibitor, which is identified by the screening method of claim 5.

11. (Withdrawn) A kit for using in the screening method of claim 5, comprising the following elements:

a) an acylated homoserine lactone represented by formula I:



wherein R is as defined above,

b) an animal cell, and

c) a means for measuring Akt activity.

12. (New) The method of claim 4, wherein inhibition of Akt activity is detected by detecting caspase activation.